following are the game changing steps for NNLX beginning

New Post Public Reply Private Reply Replies (0) Message Board
kraztkat microcaps #4563
536
following are the game changing steps for NNLX beginning August 18, 2014

this is all from mach10 post number 145 (look above, it is always there)
It has been almost four years since this was posted.

EXCERPT FROM POST 145
"Dr. Faro’s presentation led me to the conclusion that the N-Assay technology is a “game changer” across a range of distinct and dangerous conditions of bacterial infections. The identification of disease and the effective management of the individual patient is the role of the doctor. This suggests strongly that the N-Assay test represents the future direction of medical diagnosis and effective treatment through targeted and precise antibiotic infusion.

T he conclusion gained from Dr. Faro’s presentation is that there is no other methodology that can come close to matching the N-Assay technology on the significant range of diagnostic qualities detailed in 2013 by the Infectious Disease Society of America. The Society stated that a diagnostic test that could produce reliable results in one hour was needed to have a positive impact on patient care. The reliability of the test and its functional utility in a variety of important settings depended on the results being:

• Accurate
• Composed of heat stable reagents
• Having an extended shelf life
• Was portable
• Low cost relative to other methods
• Suitable for diagnosis of a broad range of clinical samples
• Required minimal technical skills
• Was rapid
• Sensitive
• Specific for each disease for which it was being used
• Provided on-demand individual testing rather than being delayed for large batched pools in order to reduce expense.

Dr. Faro indicated the current tests are simply not good enough to satisfy the full range of these critical criteria. They are also ill-suited to help deal with the array of emerging challenges related to infectious diseases. This includes the serious and growing problem of rampant antibiotic (AB) resistance caused by the almost automatic large scale generic infusion of antibiotic treatments that make up the treatment protocols in situations where a bacterial infection is diagnosed.

The rise in AB-resistant strains makes it essential that antibiotic overuse is avoided because a result of antibiotic overuse coupled with imprecisely targeted AB applications is the rapid growth in resistance by microbes that adapt to medicines to the point of rendering them ineffective. Dr. Faro commented on the fact that many doctors use antibiotics like they were “turning on a faucet”. This not only leads to a more rapid development of antibiotic resistance but entirely independent of the issue of AB resistance, the fact is that antibiotics are not simply benign substances. Antibiotics are quite dangerous drugs that can have important impacts on patient health.

An important aspect of Dr. Faro’s presentation is that the N-Assay test is machine-readable. He explained that the researchers modified the process in a way that they were able to shift to the ELISA format involving a simple plate reader. This resulted in being able to “achieve accurate test results in thirty (30) minutes rather than six hours. One breakthrough is that there is now no culture step required to achieve the rapid result.” Since it is color-coded and machine-readable ELISA eliminates inter-observer subjectivity and variability."

So we have a game changer that is four years old now and no one has the ability to get it used even once in the 16,000,000 US pregnancies in that time period?
Start with one test, get it approved, get it used, make it a game changer, get noticed, and move on to another test and start all over.
The fear is this will get passed up by better technology.




EXCERPT FROM POST 145
“NanoLogix received notification at the end of July of results for two time and temperature related tests that have been performed by a renowned independent third-party lab. In the first test, NanoLogix Tryptic Soy Agar (TSA) petri plates packed in the company's proprietary FlatPacks reached the 2-year point for room-temperature (RT) storage. The final test results for culturing of bacillus anthracis Ames (Anthrax) on the two-year-old plates were superior to the results obtained with competitor's one-week-old TSA plates, with NanoLogix's TSA plates performing as the equivalent to freshly poured plates. NanoLogix has elected to end the study, as the supply of FlatPacks that were furnished to the third-party lab two years ago predicated upon an initial four-month test for the DOD has been exhausted. The company recently completed its own testing of FlatPack packaged TSA petri plates stored for 3 years in cold storage with E-coli 0157 H7 as the test bacteria and observed results similar to those of the third-party lab 2 year RT test for Anthrax."

This testing proves longevity of the flat pack vs any other petri dish supplier. Why on earth have we not exploited this for all it is worth for the past four years to fill our coffers? This is a game changer and all we have is third party sales to create science kits for sale on Amazon. That is a huge business fail no matter how you look at it.
We don't even show our logo on that packaging. (I bought one to confirm).


Four years should be plenty enough time to start at least selling flat pack at a profit and getting noticed on the N-Assay.

Quit trying to hit the jackpot, it is not going to happen. Bring on some business partner and check the ego at the front desk.

Nanologix Inc (NNLX) Stock Research Links

NNLX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 126

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 139

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 78

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 75

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 88

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 81

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 44

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 107

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 86

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 147

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading

Top 5 Most Recently Viewed Articles

Nulogy and Kinaxis Team Up to Transform Supply Chain Dynamics

Updated Category News Views 125

Strategic Alliance Between Nulogy and Kinaxis Nulogy and Kinaxis have formed a significant partnership aimed at improving synchronization within manufacturing supply chain networks. Together, they plan to deliver innovative solutions that will streamline operations for the fast-moving consumer goods (FMCG) and life sciences sectors. Enhancing Collaboration in Supply Chain...

Continue Reading
EssentiallySports Welcomes Natasha Howard as New Correspondent

Updated Category News Views 317

EssentiallySports Welcomes Natasha Howard as New Correspondent Indiana Fever Star to Serve as Athlete Correspondent, Providing Exclusive Behind-the-Scenes Access EssentiallySports, a leading sports media publisher, has forged an exciting partnership with three-time WNBA champion Natasha Howard, known for her outstanding performances with the Indiana Fever. Howard’s new...

Continue Reading
Sinch Unveils Innovative RCS Business Service for Telcos

Updated Category News Views 194

Sinch's Cutting-Edge RCS Business Enablement Service Sinch is leading the way in transforming communication for businesses with its latest offering: the RCS Business Enablement service. This service aims to streamline RCS operations, enhancing monetization and simplifying financial management for telecom operators. As the mobile messaging landscape evolves, enterprises...

Continue Reading
Viking Therapeutics Reveals Promising Results for VK2735 in Obesity

Updated Category News Views 201

Viking Therapeutics Announces Breakthrough Findings in Obesity Treatment Viking Therapeutics, Inc. recently shared impressive news regarding the results from their Phase 2 clinical trial of VK2735, a dual agonist designed to tackle obesity. Ensuring patients can combat weight-related issues is a growing concern, and VK2735’s performance offers a beacon of hope....

Continue Reading
Elev8 Corporate Finance Announces Innovative Flat-Fee Model

Updated Category News Views 242

Elev8 Revolutionizes Bridge Financing for Businesses Elev8 Corporate Finance, a prominent private credit advisor, has unveiled an innovative compensation model aimed at empowering lower-middle-market businesses. This new flat-fee plus exit strategy unlike traditional broker commissions, promises a quicker and more cost-effective solution for securing bridge capital....

Continue Reading